BPC-157 10mg · Research brief
How to Read BPC-157 COA — Purity, Potency, Testing Explained
Short answer
Most lab managers scan a Certificate of Analysis (COA) for a single data point. The purity percentage. And file it away. That's a mistake. A COA showing 98% purity doesn't guarantee the remaining 2% isn't harmful impurities, nor does it confirm the peptide sequence is correct or that batch-specific testing occurred.
Key takeaways
- A legitimate BPC-157 COA must include a batch-specific identifier matching the vial label. Generic 'representative' COAs are compliance violations and tell you nothing about your actual material.
- HPLC purity ≥98% is the baseline standard, but the chromatogram must be included to verify the claim. Any supplier listing purity without providing the actual graph is operating without transparency.
- Molecular weight confirmation via mass spectrometry is non-negotiable. BPC-157 measures 1419.53 g/mol as the free peptide, and deviations beyond ±1 Da indicate sequence errors or wrong compound entirely.
- Peptide content (70–85% typical for acetate salts) is separate from purity and directly affects dosing accuracy. A 98% pure peptide with 75% content means 25% of the vial weight is acetate counterion, not active peptide.
- Sterility and endotoxin testing results must appear on the COA for any peptide used in cell culture or animal models. Absence of these data disqualifies the material from research use.
- Batch-to-batch variability in purity (97.8% vs 98.4%) is normal and expected. Suspiciously uniform results (always exactly 98.0%) suggest fabricated data rather than real testing.
Most lab managers scan a Certificate of Analysis (COA) for a single data point. The purity percentage. And file it away. That's a mistake. A COA showing 98% purity doesn't guarantee the remaining 2% isn't harmful impurities, nor does it confirm the peptide sequence is correct or that batch-specific testing occurred. In a 2024 review of third-party peptide suppliers conducted at a research institution, 37% of samples labeled as 'high-purity BPC-157' failed independent verification for correct molecular weight or contained undisclosed acetate salts that skewed dosing calculations.
Our team has reviewed hundreds of peptide COAs across research-grade suppliers. The gap between a legitimate document and a fabricated one isn't obvious unless you know which specific fields matter. And which testing methods are industry standard versus theatrical window dressing.
How do you properly read a BPC-157 Certificate of Analysis?
Reading a BPC-157 COA correctly requires verifying five core elements: purity percentage via HPLC (≥98%), molecular weight confirmation via mass spectrometry, peptide content percentage (often 70–85% of net weight due to acetate counterions), sterility and endotoxin testing results, and batch-specific documentation linking the test results to your exact vial. Generic COAs lacking batch numbers or showing identical chromatograms across multiple lots are red flags for non-compliant suppliers.
The key distinction most researchers miss: purity and peptide content are not the same measurement. A vial can be 99% pure BPC-157 acetate salt while containing only 75% actual peptide by weight. The rest is the acetate counterion used during synthesis. Without knowing peptide content, dosing calculations will be incorrect. This article covers how to read each section of a BPC-157 COA, what testing methods are legitimate versus performative, and which missing data points disqualify a supplier from research use.
Step 1: Verify Batch-Specific Documentation and Supplier Credentials
A legitimate COA is tied to a specific batch number that matches the label on your peptide vial. Generic COAs showing 'typical' or 'representative' results without a batch identifier are compliance violations. They tell you nothing about the material you're holding. The document should include the supplier's name, testing date, and either an internal lab accreditation or third-party testing facility name.
Look for ISO/IEC 17025 accreditation if testing was conducted in-house, or the name of a contract testing lab with traceable credentials. The testing date should be within six months of synthesis for lyophilized peptides stored at -20°C. Older COAs suggest the material has been sitting in inventory longer than stability data typically covers. We've found that suppliers using the same COA template across multiple peptides with only the compound name changed are operating outside standard quality protocols.
Batch-to-batch variability is normal in peptide synthesis. A legitimate supplier will show minor fluctuations in purity (97.8% in one batch, 98.4% in another) rather than identical 98.0% results across every lot. Suspicious uniformity suggests the COA wasn't generated from actual testing. The batch number format should be consistent with pharmaceutical industry standards. Typically a combination of synthesis date codes and sequential lot identifiers.
Step 2: Read HPLC Purity Data and Chromatogram Analysis
High-Performance Liquid Chromatography (HPLC) is the industry standard for measuring peptide purity. It separates the target peptide from synthesis byproducts, truncated sequences, and other impurities based on molecular size and polarity. The purity percentage you see on a COA represents the area under the curve for the primary peptide peak relative to all detected peaks. For research-grade BPC-157, acceptable purity is ≥98%. Anything below 95% introduces too much experimental noise.
The chromatogram itself. The graph showing peaks over time. Should be included on the COA. The target peptide appears as a dominant peak at a specific retention time (usually 10–15 minutes depending on column type), with minor peaks representing impurities. A clean chromatogram for BPC-157 shows one sharp primary peak accounting for ≥98% of total area, with baseline noise and perhaps one or two small impurity peaks below 1% each. If you see multiple peaks above 2%, the synthesis was poorly controlled.
We mean this directly: if a COA lists 98.7% purity but doesn't include the actual chromatogram, the number is unverifiable. Any supplier can type '98%' into a template. The chromatogram proves the test occurred and allows independent verification of integration accuracy. The retention time should be consistent across batches of the same peptide. Significant drift suggests column degradation or method inconsistency.
Step 3: Confirm Molecular Weight via Mass Spectrometry
Purity percentage tells you the sample is mostly one thing. Mass spectrometry confirms that thing is BPC-157 and not a similar-length peptide. BPC-157 has a molecular weight of 1419.53 g/mol (as the free peptide) or slightly higher when acetate salt is included. The COA should report either electrospray ionization mass spectrometry (ESI-MS) or matrix-assisted laser desorption/ionization (MALDI-TOF) results showing a measured mass within ±1 Da of the expected value.
The test identifies the peptide by its mass-to-charge ratio. BPC-157 appears as [M+H]⁺ at approximately 1420.5 m/z in positive-ion mode. If the COA shows a molecular weight significantly different from this range, you're not holding BPC-157. Some suppliers list 'calculated' molecular weight without providing measured data. That's a compliance gap. The measurement should be batch-specific, not a theoretical reference.
Mass spec also detects common synthesis errors like missed cleavages or wrong amino acid substitutions. If the sequence contains an error (arginine instead of lysine at position 5, for example), the molecular weight shifts by a detectable margin. A clean mass spectrum for BPC-157 shows the expected primary ion peak with minimal fragmentation. At Real Peptides, every peptide undergoes both HPLC purity analysis and mass spectrometry confirmation before batch release. Verifying sequence accuracy is non-negotiable for research integrity.
BPC-157 COA Metrics: Testing Comparison
| Testing Method | What It Measures | Acceptable Result | Why It Matters | Bottom Line |
|---|---|---|---|---|
| HPLC (High-Performance Liquid Chromatography) | Purity. Percentage of target peptide vs impurities and synthesis byproducts | ≥98% with chromatogram showing single dominant peak | Confirms synthesis cleanliness and absence of truncated sequences or reagent contamination | Without HPLC data and chromatogram, purity claims are unverifiable |
| Mass Spectrometry (ESI-MS or MALDI-TOF) | Molecular weight. Verifies correct peptide sequence and detects substitution errors | 1419.53 g/mol ±1 Da (BPC-157 free peptide) or ~1479 g/mol (acetate salt) | Distinguishes BPC-157 from similar-length peptides and confirms amino acid sequence accuracy | Measured mass must match expected value. 'calculated' entries without data are insufficient |
| Peptide Content (% w/w) | Net peptide mass as percentage of total powder weight (accounts for counterions like acetate) | 70–85% typical for acetate salts | Critical for accurate dosing. Purity measures compound cleanliness, content measures actual peptide quantity | A 98% pure peptide with 75% content means 25% of the vial weight is non-peptide mass (acetate salt) |
| Sterility Testing (USP <71>) | Bacterial and fungal contamination via 14-day incubation in growth media | No growth detected in thioglycollate or soybean-casein digest media | Prevents introducing live contaminants into cell cultures or animal models | Absence of sterility data disqualifies the peptide for any in vivo or sterile in vitro use |
| Endotoxin Testing (LAL Assay) | Lipopolysaccharide contamination from gram-negative bacteria (measured in EU/mg) | <1.0 EU/mg for research-grade peptides; <0.5 EU/mg preferred for in vivo studies | Endotoxins trigger immune responses that confound experimental results even at sub-infectious levels | High endotoxin levels invalidate immunological and inflammatory response studies |
| Heavy Metals Panel | Trace contamination from synthesis reagents or equipment (lead, arsenic, cadmium, mercury) | <10 ppm total heavy metals; individual limits per ICH Q3D guidelines | Heavy metal contamination introduces cytotoxicity and long-term accumulation risks | Absence of heavy metals testing is a red flag for peptides intended for extended dosing protocols |
What If: BPC-157 COA Scenarios
What If the COA Shows 99% Purity But No Chromatogram?
Request the full chromatogram from the supplier immediately. A purity claim without supporting HPLC data is unverifiable. Any template can display '99%' without proving the test occurred. The chromatogram shows the actual peak integration and allows independent confirmation that impurities are below acceptable thresholds. If the supplier refuses or provides a generic chromatogram with no batch number, the material should not be used for research. The absence of chromatogram documentation is the single clearest indicator of a non-compliant supplier cutting corners on quality assurance.
What If the Molecular Weight Is Off by 3–5 Daltons?
A deviation of 3–5 Da from the expected 1419.53 g/mol molecular weight for BPC-157 indicates either a sequence error (wrong amino acid incorporated during synthesis) or significant contamination with a structurally similar peptide. Mass spectrometry at research-grade resolution should match within ±1 Da. Anything beyond that margin suggests the peptide isn't what the label claims. Do not proceed with the material. Contact the supplier for a replacement or refund, and request a new COA with corrected mass spec data. This isn't a minor variance. It's a fundamental quality failure.
What If Peptide Content Is Listed at 65% Instead of 75–85%?
Peptide content below 70% suggests either excessive acetate counterion content or synthesis issues that introduced non-peptide mass into the final product. While lower peptide content doesn't necessarily mean the material is unsafe, it does mean your dosing calculations will be significantly off if you assume the vial contains 100% active peptide. Recalculate your dosing protocol to account for the actual peptide content. If the COA lists 65% content, a 5mg vial contains only 3.25mg of actual BPC-157. Suppliers with consistently low peptide content are using synthesis or lyophilization methods that introduce unnecessary filler mass.
What If the COA Lacks Sterility or Endotoxin Data?
Refuse to use the peptide for any in vivo studies or sterile cell culture work. Sterility testing via USP <71> and endotoxin quantification via LAL assay are mandatory for research-grade peptides. Their absence means the material wasn't tested for bacterial, fungal, or lipopolysaccharide contamination. Introducing untested peptides into animal models or sterile environments risks confounding your experimental results with immune responses triggered by contaminants rather than the peptide itself. A supplier omitting these tests is operating outside standard biosafety protocols and should not be used for funded research.
The Unfiltered Truth About BPC-157 COAs
Here's the honest answer: most peptide suppliers know that researchers don't read COAs carefully. They count on you scanning for a purity number and moving on. That's why fabricated or recycled COAs are disturbingly common in the research peptide market. The business model depends on opacity: if you don't know what batch-specific chromatograms look like, you won't notice when the same graph appears on three different lots. If you don't understand peptide content versus purity, you won't realize your dosing has been wrong for six months.
The evidence is straightforward. A 2023 independent analysis of peptides purchased from online research suppliers found that 22% of samples failed to match their COA claims when subjected to third-party HPLC and mass spec verification. The peptides weren't counterfeit. They were real compounds, just not the stated purity or correct sequence. The suppliers weren't lying outright. They were relying on outdated testing, batch substitution, or documents that were never tied to the specific material being shipped.
This isn't about distrust for its own sake. It's about recognizing that the peptide supply chain has serious quality control gaps, and your responsibility as a researcher is to verify every input to your experimental protocol. A single contaminated or mislabeled peptide invalidates months of work. Reading a COA properly. Checking for batch numbers, demanding chromatograms, confirming molecular weight, and verifying sterility data. Is the baseline standard for maintaining research integrity. If your supplier can't or won't provide complete documentation, you're working with the wrong supplier.
Our experience working with research teams has shown a consistent pattern: labs that implement strict COA verification protocols before accepting new peptide batches experience fewer unexplained experimental failures and more reproducible results. The time spent reading documentation upfront prevents the significantly larger time cost of troubleshooting contaminated or degraded peptides after they've already entered your workflow. Discover our commitment to transparency and precision across our full peptide collection. Every batch ships with complete third-party testing documentation.
If the COA for your current BPC-157 batch is missing any of the five core elements outlined in this article. Batch-specific HPLC chromatogram, mass spectrometry confirmation, peptide content percentage, sterility testing results, or endotoxin quantification. Request the missing data immediately. A legitimate supplier will provide it within 24–48 hours. If they can't, or if they deflect with vague assurances about 'industry standards', you're holding material that hasn't been properly characterized. That's not acceptable for research-grade work, and it shouldn't be acceptable to you.
References
Peer-reviewed sources on BPC-157 indexed in PubMed, listed for research context. Real Peptides supplies BPC-157 for laboratory research use only.
- Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS journal : the musculoskeletal journal of Hospital for Special Surgery, 2025. PMID 40756949. doi:10.1177/15563316251355551
- Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals (Basel, Switzerland), 2025. PMID 40005999. doi:10.3390/ph18020185
- Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Current reviews in musculoskeletal medicine, 2025. PMID 40789979. doi:10.1007/s12178-025-09990-7
- Stable Gastric Pentadecapeptide BPC 157 and Intestinal Anastomoses Therapy in Rats-A Review. Pharmaceuticals (Basel, Switzerland), 2024. PMID 39204186. doi:10.3390/ph17081081
- From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management. International journal of molecular sciences, 2026. PMID 41898733. doi:10.3390/ijms27062876
- BPC-157 and Its Novel Hybrid Analogs as Inhibitors of Acetylcholinesterase. International journal of molecular sciences, 2026. PMID 42278509. doi:10.3390/ijms27114984
- Protective effects of BPC 157 in rats with experimentally induced lower extremity ischemia-reperfusion injury. Scientific reports, 2026. PMID 42204242. doi:10.1038/s41598-026-55449-1
- Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Joint diseases and related surgery, 2026. PMID 42542926. doi:10.52312/jdrs.2026.2951
Build a pack
Researching more than one compound?
Build a multi-vial pack and the discount applies automatically as you add doses.
Questions
RESEARCH USE ONLY · NOT EVALUATED BY THE FDA